IGC Pharma, Inc. (IGC): R&D Expense

Annual figures by period end, from SEC filings.

Not updated since 2025-03-31. No annual report in US GAAP has been filed since. Companies that switch to IFRS reporting, as many foreign filers do, or stop filing are not updated here.

$3.65M
Year ended 2025-03-31
$4.29M
Trailing 12 months to 2025-09-30
+16.2%
3-year compound annual growth
+29.3%
5-year compound annual growth
$3.77M2018-03-31: $137.0K2019-03-31: $1.26M2020-03-31: $1.01M2021-03-31: $929.0K2022-03-31: $2.33M2023-03-31: $3.46M2024-03-31: $3.77M2025-03-31: $3.65M$3.65M
2018-03-31 R&D Expense (USD) 2025-03-31
Period endedR&D ExpenseChange YoYSource filing
2025-03-31$3.65M-3.1%2025-06-27, From 2024-04-01
2024-03-31$3.77M+9.0%2025-06-27, From 2023-04-01
2023-03-31$3.46M+48.5%2024-06-24, From 2022-04-01
2022-03-31$2.33M+150.8%2023-07-07, From 2021-04-01
2021-03-31$929.0K-8.1%2022-06-23, From 2020-04-01
2020-03-31$1.01M-19.5%2021-06-14, From 2019-04-01
2019-03-31$1.26M+816.8%2020-07-13, From 2018-04-01
2018-03-31$137.0Kn/a2019-06-14, From 2017-04-01